Response criteria represent the standard by which the efficacy of therapeutic agents is determined in cancer trials. The most widely used criteria are based on the anatomic measurement of solid tumors. Because bone metastases are typically located in irregularly shaped bones and are difficult to measure with rulers, they have been previously considered unmeasurable disease. New developments in cancer response criteria have increased awareness of the importance of the response of bone metastases to therapy. The recently updated Response Evaluation Criteria in Solid Tumors (RECIST 1.1) now consider bone metastases with soft tissue masses > 10 mm to be measurable disease. Response criteria specific to bone metastases have been developed at The University of Texas MD Anderson Cancer Center (MDA criteria) and can be used to assess therapeutic response in numerous types of bone metastases. Functional imaging criteria, such as the recently developed Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) allow response to be measured in the absence of anatomic change through assessment of metabolic activity. As monitoring tumor response of bone metastases becomes more important in the management of cancer, so does the demand on radiologists and nuclear medicine physicians for accurate interpretation of the behavior of these lesions. This article reviews anatomic, bone, and metabolic response criteria, providing illustrations for the interpretation of therapy-induced change in bone metastases.
Introduction
An estimated 569,490 Americans are expected to die of c ancer in 2 01 0, acc ount ing fo r a p p roxim at el y 25% of the overall mortality (1). Bone metastases are a common manifestation of advanced disease with autopsy studies showing an incidence of 33-36% in patients with lung cancer (2, 3) , 68% in prostate cancer (3) , and 73% in breast cancer (2, 3) . While many patients receive therapy at major cancer centers, numerous other patients choose local or regional hospitals, and most imaging studies include the skeleton secondarily if not primarily (e.g. chest radiography, body computed tomography [CT] ). Thus, the appearance and behavior of bone metastases can be detected on a wide variety of imaging studies that are performed for many different indications.
Response criteria represent the standard by which the efficacy of new therapeutic agents is determined in cancer treatment trials. The most commonly used set of criteria is the Response Evaluation Criteria in Solid Tumors (RECIST). These and similar anatomic criteria focus predominantly on the physical measurement of solid tumors. Disease that is not easily measurable with a ruler or calipers, such as most bone metastases, is designated as unmeasurable. Cancer patients with no measurable disease (e.g. individuals with bone-only metastases following the resection of a primary tumor) are often ineligible for clinical trials, which may be the only available source of therapy. Therefore, the absence of measurable tum o r s c a n s i g n i f i c a n t l y a f f e c t p a t i e n t d i s e a s e m a nagement. This article reviews anatomic (RECIST 1.1), bone (MD Anderson [MDA]), and metabolic (Positron Emission Tomography Response Criteria in Solid T u m o r s [ P E R C I S T ] ) c a n c e r r e s p o n s e c r i t e r i a , w i t h a focus on the developing role of bone metastases and the interpretation of the treatment response of bone metastases seen on imaging studies.
RECIST 1.1
Change in tumor size following therapy, also known as objective response (4, 5) , is a robust indicat o r o f o u t c o m e i n t h e t r e a t m e n t o f n u m e r o u s s o l i d tumors (6) (7) (8) (9) and forms the basis for anatomic response criteria. RECIST (10) , updated to RECIST 1.1 in 2009 (11) , was designed to standardize the assessment of therapeutic response to allow meaningful comparison of drug efficacy among individuals in the same study and across different studies (12, 13) . RECIST 1.1 specifies that up to 5 target lesions, representing all affected organ systems but with no more than 2 target lesions per organ, be selected for measurement t h r o u g h o u t t h e c o u r s e o f a t h e r a p e u t i c t r i a l . T o b e considered as target lesions, at baseline nodules must measure ≥ 10 mm on CT (or twice the slice thickness if the interval is > 5 mm), the short axes of lymph nodes must measure ≥ 15 mm on CT (recommended slice thickness is < 5 mm), palpable masses must be ≥ 10 mm as measured with calipers; and lung lesions must be ≥ 20 mm, clearly delineated, and surrounded by lung parenchyma on chest radiographs. Lesions may be measured using CT or magnetic resonance imaging (MRI), but CT is preferred in most situations because of the variability of MRI scan parameters. Measurements made using ultrasonography are not acceptable because of operator dependency and lack of objective reproducibility.
A c c o r d i n g t o R E C I S T 1 . 1 , d r u g e f f i c a c y i s p r imarily determined by the sum of the measurements of the greatest longitudinal dimension of each target lesion. One of the differences between RECIST and RECIST 1.1 is that bone metastases with soft tissue masses measuring ≥ 10 mm are now accepted as target lesions. The soft tissue component is to be measured in an identical manner to that used for other target lesions (Fig. 1) . Measurements are to be made in the plane of acquisition (typically axial for CT unless isotropic reconstructions are performed). The largest lesions are preferred if they are clearly and reproducibly measurable (e.g. the largest well-defined lesion is preferred over larger, ill-defined lesions), and no previously irradiated lesion is eligible as a target lesion unless it demonstrates progression after irradiation. Therefore, a careful search of the medical record for previous therapeutic radiation exposure is indicated prior to the selection of a bone metastasis as a target lesion.
RECIST 1.1 states that CT is "the best currently available and reproducible method to measure lesions selected for response assessment" (11) . However, MRI has been shown superior to CT in delineating the ext e n t o f p r i m a r y b o n e t u m o r s ( w h i c h a r e s i m i l a r t o t a r g e t b o n e l e s i o n s b e c a u s e t h e y t y p i c a l l y p r o d u c e large soft tissue masses) and their relationship to adjacent structures (14, 15) . The value of the high soft tissue contrast resolution o f M R I w a s s h o w n i n a prospective study comparing MRI and CT for the detection of locally recurrent tumors in 49 patients following the resection of musculoskeletal malignancies (16) . In the 33 biopsy-proven locally recurrent tumor nodules, MRI demonstrated sensitivity, specificity, and accuracy of 82.5%, 96.3%, and 92.6%, respectively; CT values for sensitivity, specificity, and accuracy were 57.5%, 96.3%, and 85.0%, respectively. MRI scans with and without the use of intravenous gadolinium contrast can be considered for the follow-up of measurable bone lesions. RECIST 1.1 specifies contrast administration for both MRI and CT scans.
The 4 response categories included in RECIST 1.1 are complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD) (Table 1). CR is defined as the disappearance of all target lesions and reduction of the short axes of target lymph nodes to < 10 mm. Fludeoxyglucose F 18 (FDG) positron emission tomography (PET) can be used in place o f b i o p s y t o v e r i f y C R w h e n a r e s i d u a l m a s s i s thought to represent scarring or fibrosis. The PR category requires a decrease in the sum of the diameters of all target lesions by ≥ 30%; the patient's baseline sum of these diameters is the reference standard. PD requires an increase of ≥ 20% (with at least a 5-mm increase) in the sum of target lesion diameters; again, the patient's smallest recorded sum of these diameters is the reference standard. Additionally, the interval development of a malignant FDG uptake pattern is considered an indicator of PD unless it corresponds to an anatomically stable lesion. The metastasis is to be confirmed on contemporaneous or follow-up CT (Fig.  2) . The SD category includes all patients whose dis-ease activity does not meet the requirements of the other 3 categories using the smallest previous sum of lesion diameters as the reference standard.
RECIST 1.1 designates numerous lesions as unmeasurable. These include small tumors (nodules with a short-axis dimension < 10 mm), leptomeningeal disease, lymphangitic spread, inflammatory breast disease, pericardial/pleural effusions, palpable abdominal masses/organomegaly not reproducible on imaging studies, lesions surrounded by postradiation scar tissue, and bone metastases without soft tissue masses measuring ≥ 10 mm (the large majority of bone metastases). While no focus of unmeasurable disease can be used as a target lesion, the progression of such tumors can have an effect on the RECIST response assessment under the designation of unequivocal progression of nontarget lesions. In general, progression of nontarget lesions is to be estimated as a 20% increase in the sum of the greatest tumor diameters, which is calculated to be a 73% increase in vol u m e , b y t h e a u t h o r s o f t h e R E C I S T c r i t e r i a (11) . Therefore, frank progression of bone metastases on any imaging modality can contribute to the classification of overall patient response through the designation of unequivocal progression (Fig. 3) . 
MDA Criteria
The field of oncology has seen several generations of cancer response criteria. The International Union Against Cancer (UICC) (17) and the World Health Organization (WHO) (4) published criteria in 1977 and 1979, respectively. While at the time representing the most sophisticated attempts to standardize the evaluation of tumor response, these criteria were published before the widespread availability of CT. Both sets of criteria, which have been largely supplanted by RECIST and RECIST 1.1, consider bone metastases to be measurable disease. Additionally, the WHO criteria include radiograph-based guidelines for the interpretation of bone metastases; however, these guidelines were not adopted by RECIST or RECIST 1.1. The resultant void regarding the evaluat i o n o f b o n e m e t a s t a s e s l e d t o t h e d e velopment of bone-specific response criteria at The University of Texas MD Anderson Cancer Center in 2004 (18) . The MDA criteria updated the UICC and WHO bone response criteria by expanding radiographic assessment and incorporating both CT and MRI.
The MDA criteria divide response into 4 standard categories (CR, PR, PD, and SD) and include quantitative and qualitative assessments of the behavior of bone metastases ( Table 2 ). PR is defined as a decrease of ≥ 50% i n t h e s u m o f t h e p e r p e n d i c u l a r measurements of any lesion and PD as an increase of ≥ 25% in this sum. No change < 25% increase or < 50% decrease in size of measurable lesions < 25% subjective increase or < 50% subjective decrease in size of ill-defined lesions No new bone metastases *Measurements are based on the sum of a perpendicular, bidimensional measurement of the greatest diameters of each individual lesion.
Abbreviations: XR, radiography; CT, computed tomography; SS, skeletal scintigraphy; MRI, magnetic resonance imaging. According to the MDA criteria, CR is defined as complete sclerotic fill-in of lytic lesions on radiographs or CT, the restoration of normal bone density on radiography or CT, the disappearance of abnormal tracer uptake on skeletal scintigraphy (SS), and the normalization of signal intensity on MRI (Fig. 4) . The PR category includes the development of a sclerotic rim (Fig. 5) or partial (rather than complete) sclerotic fill-in of lytic metastases on radiography or CT; ≥ 50% decrease in t h e s u m o f t h e p e r p e n d i c u l a r m e a s u r ements of measurable lesions on radiography, CT, or MRI (Fig. 6) ; ≥ 50% subjective decrease in the sum of the perpendicular measurements of unmeasurable (ill-defined) lytic or blastic lesions on radiography, CT, or MRI that cannot be accounted for by changes in obliquity or slice placement; and ≥ 50% subjective decrease in tracer uptake on SS (Fig. 7) . A caveat to the PR designation involves the osteoblastic flare phenomenon. Interval visualization of sclerotic lesions or lytic lesions with sclerotic rims, in the setting of other signs of PR, does not indicate disease progression but the healing of previously inconspicuous lesions (19) . Osteoblastic flare cannot be diagnosed if any preexisting lesions show signs of progression (e.g. enlargement of lytic lesions, development of new lytic lesions) (Fig. 8) . PD is defined as > 25% increase in the sum of the perpendicular measurements of any measurable lesion on radiography, CT, or MRI; > 25% subjective increase in the size of unmeasurable (ill-defined) lytic or blastic lesions on XR, CT or MRI t h a t c a n n o t b e a c c o u n t e d f o r b y o b l i q u i t y o r s l i c e placement; > 25% subjective increase in tracer uptake on SS; or the development of new metastases. An inc r e a s e i n t r a c e r u p t a k e o n S S m a y n e e d c o r r e l a t i o n with other imaging studies to exclude the scintigraphic flare phenomenon, which is typically seen within the first 3 months after therapy. Scintigraphic flare occurs when healing sclerosis results in more tracer uptake than was caused by the untreated lesion (Fig. 9) (20-24) . SD is defined as < 25% increase or < 50% decrease in size or no change in measurable lesions and no new lesions. 
I n a s t u d y c o m p a r i n g t h e M D
A , U I C C , a n d WHO criteria in 41 breast cancer patients with bone-only metastases, the MDA criteria were shown to better differentiate responders to chemotherapy from nonresponders and were the only set of criteria to correspond to progression-free survival (25) . According to the MDA criteria, time to disease progression was 5.5 months for nonresponders and 23.3 months for responders (P = 0.025), compared with 10.4 months and 12.4 months, respectively, according to the WHO criteria (P = 0.55 ) . T h e M D A c r i t e r i a identified nonresponders earlier and better correlated with clinical response in the first 2-6 months of therapy than did the WHO criteria. Early signs of disease progression are valuable, allowing the halting of ineffective therapy in a timely fashion and the possible substitution of effective therapy. In addition to their utility for guiding treatment decisions, the MDA bone response criteria closely reflect the behavior of bone metastases on radiography and CT and can be used as guidelines for the interpretation of these studies whether or not a patient is enrolled in a therapeutic trial. The MDA criteria can be considered for use in conjunction with other cancer response criteria or in patients with bone-only metastases and no measurable disease.
PERCIST
PET has the potential to revolutionize the definition of measurable tumors because it introduces imaging criteria based on function. The regular, well-defined tumor margins that are necessary for reproducible anatomic measurements are of lesser importance in functional imaging. FDG is a radiolabeled form of glucose that cannot be metabolized and therefore accumulates in cells, which take up the molecules as if they were normal glucose. Through this accumulation, FDG activity acts as a surrogate for glucose metabolism (26) . Since many malignancies are highly metabolic and accumulate FDG, it is the most commonly used PET agent for oncologic indications. The following review of the PERCIST criteria includes many of the concepts discussed in the source article (27) .
Evaluation of tumor response with FDG PET has several advantages over anatomically based criteria. Some chemotherapeutic agents are cytostatic rather than cytocidal and therefore do not result in a profound change in tumor size despite their effectiveness (28) (29) (30) , and some malignancies, such as gastrointestinal stromal tumors, do not demonstrate PR through a large decrease in size (31) . By reflecting change in tumor metabolism, FDG PET scanning can provide a method by which tumor response can be measured in the absence of marked anatomic change (32) . A dec r e a s e i n F D G u p t a k e h a s b e e n s h o w n t o i n d i c a t e treatment response and/or improved survival times in patients with solid tumors such as breast cancer (33, 34) , esophageal cancer (35-37), lung cancer (38, 39) , osteosarcoma (40, 41) , and others (42) . FDG PET has also been shown to provide more rapid response data than anatomic measurements (43) (44) (45) . (49) , t h e N e t h e r l a n d s S o c i e t y o f N u c l e a r Medicine (50) , and the National Cancer Institute (51). PERCIST, published in the Journal of Nuclear Medicine (27) , represents the most recent effort to create standardized criteria that accurately reflect response in t h e l a r g e s t n u m b e r o f m a l i g n a n c i e s . T h e P E R C I S T c r i t e r i a u t i l i z e t h e c o n c e p t o f t u m o r r e s p o n s e a s a continuous variable. Because tumor response is inherently continuous, discrete categorization (e.g. CR, PR, PD, and SD) may result in the loss of important information (27, 28, 52) . Therefore, PERCIST specifies t h a t t h e p e r c e n t a g e o f c h a n g e i n m e t a b o l i c a c t i v i t y from baseline and the number of weeks from the ini t i a t i o n o f t h e r a p y b e r e c o r d e d t o p r o v i d e a c o n t inuous plot of tumor activity.
The primary determinant of response using PERCIST is the standardized uptake value (SUV), a semiquantitative measure of activity that is most commonly calculated by dividing the measured tumor activity by injected dose/body weight (53) . Among the many variants of SUV (e.g. maximum SUV, mean SUV), SUV corrected for lean body mass ( S U L ) w a s s e l e c t e d f o r u s e w i t h P E R C I S T b e c a u s e SUL has been shown to be less susceptible to variations in patient body weight than the other SUV metrics (54, 55) . PERCIST specifies that the SUL peak is to be obtained on the single most active lesion on each scan. SUL peak is the average of the activity within a spherical region of interest measuring 1.2 cm in diameter (for a volume of 1 cm 3 ) centered at the most a c t i v e p o r t i o n o f t h e t u m o r . T h e S U L p e a k m a y b e located in a different lesion on a follow-up scan be-cause the current most avid lesion is to be measured. Using a concept similar to RECIST, it is also recommended that a sum of the activity of up to 5 target lesions (no more than 2 per organ) be measured as a secondary determinant of response. Future studies will show which of the 2 methods of response determination most accurately reflects treatment outcome.
An alternative metric that can be used to determine FDG avidity according to the PERCIST criteria is total lesion glycolysis (TLG). This is a measure of the FDG uptake of the entire tumor above a pre-set threshold and is calculated by multiplying the mean SUV by total tumor volume (mL) (27, 56) TLG has been tested in several malignancies and has produced mixed results in comparison to SUV metrics, showing a weaker correlation with response in bone metastases in breast cancer patients (57) and in sarcomas (41, 58) b u t e q u a l o r b e t t e r i n e s o p h a g e a l , l u n g , g a s t r i c a n d rectal cancer (59) (60, 61) . PERCIST suggests that SUL p e a k a n d T L G c a n b e m e a s u r e d s i m u l t a n e o u s l y i n order to further evaluate the efficacy of TLG. For further specifics regarding PET scanning, such as information regarding patient preparation and scan acquisition, please see the PERCIST source article by Wahl et al. (55) .
PERCIST defines 4 response categories (Table 3 ) in addition to plotting tumor response in weeks from the initiation of therapy. Complete metabolic response is defined as the disappearance of metabolic tumor activity in target and nontarget lesions. Residual FDG uptake can be seen despite effective therapy, possibly due to macrophage activity (62) , and therefore PERCIST define complete metabolic response as a d e c r e a s e i n t u m o r S U L t o t h e l e v e l o f s u r r o u n ding normal tissue. Partial metabolic response is defined b y a d e c l i n e o f > 3 0 % i n S U L p e a k w i t h a t least a 0.8-unit decline (Fig. 10) . Progressive metabolic disease includes an increase of > 30% in SUL peak with at least a 0.8-unit increase, a visible increase in the extent of FDG uptake (increase in the color field representing FDG uptake), or the development of new lesions. In the absence of clear evidence of disease progression on the fused CT image, new FDG-avid foci are to be verified on a follow-up scan 1 month after discovery. Stable metabolic disease is the absence of change or mild changes that do not meet the minimum qualifications of the other categories. Anatomic change in t u m o r s i z e r e m a i n s a n i m p o r t a n t f a c t o r u n d e r PERCIST and is to be measured according to RECIST 1.1. If lesions increase or decrease in size without a corresponding change in metabolic activity, disease p r o g r e s s i o n o r r e s p o n s e i s t o b e v e r i f i e d o n a f o llow-up scan.
When evaluating the potential role of functional imaging modalities such as PET, the RECIST working group decided that there was "not sufficient standardization or evidence to abandon anatomical assessm e n t o f t u m o r b u r d e n " (11) . Considering the numerous areas of potential variability that must be o v e r c o m e i n t h e a c q u i s i t i o n a n d i n t e r p r e t a t i o n o f PET/CT scans, this hesitation is understandable. Nevertheless, if the attempt at standardization represented by PERCIST is successful, FDG PET/CT may be considered as an alternative source of disease measurement in future revisions of the RECIST criteria. Functional imaging criteria can also be considered for use in conjunction with anatomic criteria such as RECIST or MDA (Table 4) . Does not meet other criteria * Primary outcome determination is measured on the single most active lesion on each scan (not necessarily the same lesion). Secondary outcome determination is the summed activity of up to 5 most intense lesions (no more than 2 lesions per organ).
Abbreviations: SUL, standardized uptake value using lean body mass; TLG, total lesion glycolysis. 
Conclusion
The MDA criteria can allow more bone lesions to be considered measurable disease than does the RECIST 1.1 system by allowing physical measurement of well-defined bone lesions regardless of soft tissue extension, by allowing regimented subjective assessment of ill-defined lesions, and by taking into account characteristic behaviors such as the development of healing sclerosis. Metabolic imaging criteria can allow bone metastases to be measured in the absence of a n a t o m i c c h a n g e b y a s s e s s i n g t u m o r m e t a b o l i s m . Response criteria are of crucial importance to the care of many cancer patients, and the tumor response assessment of bone metastases is assuming a greater role in therapeutic management. Knowledge of the fundamental concepts of tumor response criteria (anatomic, bone, and functional) and the appearance o f b o n e m e t a s t a s e s a s t h e y r e s p o n d t o t r e a t m e n t o r progress can aid in the interpretation of studies in a manner that will render them of optimal value to the patient and clinician.
